Benefit assessment in Germany.
Hasford
Joerg
J
Lehmacher
Walter
W
D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D000077144:Clopidogrel; D057186:Comparative Effectiveness Research / Q000592:standards; D005858:Germany; D006077:Government Agencies / Q000191:economics; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D009313:National Health Programs; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D010975:Platelet Aggregation Inhibitors; D000069036:Insulin Glargine; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin